→ The FDA is giving Pfizer’s tafamidis a quick look over in advance of a likely approval. The agency will give the drug a priority review for transthyretin amyloid cardiomyopathy — offering to lop months off the process. Of course, that presumes the FDA will be back in business soon.
→ Clarivate Analytics is merging with Churchill Capital. The combined company will have an enterprise value of $4.2 billion.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription